Total
0
Shares
InteliCare (ASX:ICR)- CEO and Managing Director, Jason Waller
CEO and Managing Director, Jason Waller
Source: InteliCare
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InteliCare Holdings (ICR) has developed a new suite of analytics to provide enhanced functional capacity to its InteliLiving remote care package
  • The company’s InteliLiving Health Metrics help capture and record health data and is available through both manual and automated methods or through smart health-tracking devices like Fitbit
  • Using the InteliLiving app, members of a care team can view and track multiple health metrics on daily, weekly, monthly or longer time frames
  • InteliLiving Health Metrics is the first step in the company’s strategy to further increase market share and competitive advantage, by leveraging its proprietary software platform and AI
  • The company says this represents a significant new milestone in the technological and functional capability of its flagship product
  • Shares are up 14.3 per cent, trading at 32 cents per share

Australian health tech company InteliCare Holdings (ICR) has developed a new suite of analytics to provide enhanced functional capacity to its InteliLiving remote care package.

InteliCare focuses on developing proprietary systems and products to address the growing global burdens in the aged care sectors. It looks to do this through its InteliLiving smart home enabled analytics, which provides independent adults and their care team with proactive insights and alerts based on daily activities and routines.

InteliLiving Health Metrics helps capture and record health data, available through both manual and automated methods or through smart health tracking devices like Fitbit.

Using the InteliLiving app, members of a care team can view and track multiple health metrics on daily, weekly, monthly or longer time frames.

When paired with InteliLiving passive sensors, daily routine data and proactive analytics, InteliLiving’s health metrics can detect emerging health and wellness issues, enabling the care team to take a proactive approach to improving the health journey of the client.

InteliLiving Health Metrics is the first step in the company’s strategy to further increase market share and competitive advantage, by leveraging its proprietary software platform and AI.

The company says this represents a significant new milestone in the technological and functional capability of its flagship product.

The initial product will be a free addition to the current suite in order to leverage competitive advantage and gain market share. As further advances are made to the value offering, additional upsell subscription tiers will become available.

The company say mobile health apps and associated remote patient monitoring are a large and growing segment of the U.S. $35 billion (roughly A$45 billion) total digital health market. According to the company, the new product unlocks further growth opportunities via its seamless integration with FitBit, which saw a total of 1.2 million sold in the second half of 2020 in Australia.   

InteliCare is now looking to develop further integrations with newly sophisticated and affordable, TGA-approved wearable sensors that will further automate data gathering.

Shares are up 14.3 per cent, trading at 32 cents at 1:15 pm AEDT.

ICR by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.